

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Robert J. Chambers, et al:

APPLICATION NO.: To Be Assigned : Examiner: To Be Assigned

FILING DATE: Herewith : Group Art Unit: To Be Assigned

TITLE: Nicotinamide Biaryl Derivatives Useful As :
Inhibitors of DE4 Isozymes-----
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office. Due to the large number of references to be cited on the PTO-FB-A820, the references have not been enclosed. To review the references, please see the parent application, U.S. Serial No. 10/062,813, filed January 31, 2002.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

July 2, 2003Robert T. RonauRobert T. Ronau
Attorney for Applicant(s)
Reg. No. 36,257Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910EXPRESS MAIL NO. 2010411465505